Page 138 - Read Online

Page 132 Chan et al. J Transl Genet Genom 2024;8:13-34 https://dx.doi.org/10.20517/jtgg.2023.36

31. Gregory GA, Robinson TIG, Linklater SE, et al; International Diabetes Federation Diabetes Atlas Type 1 Diabetes in Adults Special
Interest Group. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.
Lancet Diabetes Endocrinol 2022;10:741-60. DOI
32. Metcalfe KA, Hitman GA, Rowe RE, et al. Concordance for type 1 diabetes in identical twins is affected by insulin genotype.
Diabetes Care 2001;24:838-42. DOI
33. Sharp SA, Weedon MN, Hagopian WA, Oram RA. Clinical and research uses of genetic risk scores in type 1 diabetes. Curr Opin
Genet Dev 2018;50:96-102. DOI PubMed PMC
34. Noble JA, Valdes AM. Genetics of the HLA region in the prediction of type 1 diabetes. Curr Diab Rep 2011;11:533-42. DOI
PubMed PMC
35. Barrett JC, Clayton DG, Concannon P, et al; Type 1 diabetes genetics consortium. genome-wide association study and meta-analysis
find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-7. DOI PubMed PMC
36. Redondo MJ, Geyer S, Steck AK, et al; Type 1 Diabetes TrialNet Study Group. A Type 1 diabetes genetic risk score predicts
progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care 2018;41:1887-94. DOI
37. Bonifacio E, Beyerlein A, Hippich M, et al; TEDDY Study Group. Genetic scores to stratify risk of developing multiple islet
autoantibodies and type 1 diabetes: a prospective study in children. PLoS Med 2018;15:e1002548. DOI PubMed PMC
38. remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The
Canadian-European randomized control trial group. Diabetes 1988;37:1574-82. PubMed
39. Mullard A. FDA approves anti-CD3 antibody to delay type 1 diabetes onset. Nat Rev Drug Discov 2023;22:6-7. DOI PubMed
40. Herold KC, Bundy BN, Long SA, et al; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 antibody, teplizumab, in relatives at
risk for type 1 diabetes. N Engl J Med 2019;381:603-13. DOI PubMed PMC
41. Ramos EL, Dayan CM, Chatenoud L, et al; PROTECT Study Investigators. Teplizumab and β-Cell function in newly diagnosed type
1 diabetes. N Engl J Med 2023;389:2151-61. DOI
42. Padilla-Martínez F, Collin F, Kwasniewski M, Kretowski A. Systematic review of polygenic risk scores for type 1 and type 2
diabetes. Int J Mol Sci 2020;21:1703. DOI PubMed PMC
43. Sims EK, Carr ALJ, Oram RA, DiMeglio LA, Evans-Molina C. 100 years of insulin: celebrating the past, present and future of
diabetes therapy. Nat Med 2021;27:1154-64. DOI PubMed PMC
44. Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes
Technol Ther 2017;19:S25-37. DOI PubMed PMC
45. Nathan DM, Genuth S, Lachin J, et al; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment
of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med
1993;329:977-86. DOI
46. Buzzetti R, Tuomi T, Mauricio D, et al. Management of latent autoimmune diabetes in adults: a consensus statement from an
international expert panel. Diabetes 2020;69:2037-47. DOI PubMed PMC
47. Imagawa A. Two types of fulminant type 1 diabetes mellitus: immune checkpoint inhibitor-related and conventional. J Diabetes
Investig 2021;12:917-9. DOI PubMed PMC
48. Bornstein SR, Rubino F, Ludwig B, et al. Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nat Metab
2021;3:289-92. DOI
49. Ata A, Jalilova A, Kırkgöz T, et al. Does COVID-19 predispose patients to type 1 diabetes mellitus? Clin Pediatr Endocrinol
2022;31:33-7. DOI PubMed PMC
50. Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev
Endocrinol 2021;17:11-30. DOI PubMed PMC
51. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005;95 Suppl 1:S144-50. DOI
PubMed
52. Akturk HK, Kahramangil D, Sarwal A, Hoffecker L, Murad MH, Michels AW. Immune checkpoint inhibitor-induced type 1
diabetes: a systematic review and meta-analysis. Diabet Med 2019;36:1075-81. DOI PubMed PMC
53. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med
2018;378:158-68. DOI PubMed
54. Ugai T, Sasamoto N, Lee HY, et al. Is early-onset cancer an emerging global epidemic? Nat Rev Clin Oncol 2022;19:656-73. DOI
PubMed PMC
+
55. Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8 T cell dysfunction across
chronic infection, cancer and autoimmunity. Nat Immunol 2021;22:809-19. DOI PubMed PMC
56. Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group. Glycaemic durability of an early
combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes
(VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet 2019;394:1519-29. DOI PubMed
57. Cheung JTK, Yang A, Wu H, et al. Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays
insulin initiation in type 2 diabetes: a propensity score-matched cohort study. Diabetes Metab Res Rev 2023:e3711. DOI
58. Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications
(the diabetes & aging study). Diabetes Care 2019;42:416-26. DOI
59. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl